Accel
Accel is a venture capital firm founded in 1983 and based in Palo Alto, California, with additional offices in San Francisco, London, and Bangalore. It focuses on early and growth-stage technology startups, investing across software, cloud, data analytics, mobile technology, consumer services, fintech, security, healthcare, and information technologies. Accel seeks to partner with entrepreneurs to build world-class companies that define new categories and drive growth. Its portfolio includes notable technology companies such as Atlassian, Dropbox, Slack, Spotify, Etsy, Cloudera, DJI, Braintree, and Lookout Security, among others.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Simulation
True Anomaly
Series C in 2025
True Anomaly develops space security and resilience solutions by integrating autonomous spacecraft operations, artificial intelligence, and mission-specific software. The company designs, builds, and fields technologies that enable secure and sustainable access to orbital environments for defense agencies, allied governments, and commercial operators. Its offerings improve orbital situational awareness, maintain operational continuity, and support long-term space sustainability across critical infrastructure and strategic missions.
Turbine
Series A in 2022
Turbine Ltd, established in 2015 and headquartered in Budapest, Hungary, specializes in computational biology for cancer drug development. The company's core product is a predictive model that simulates cellular behavior, aiding in the discovery, preclinical testing, and development of cancer therapies. Turbine's platform leverages proprietary Simulated Cell technology and artificial intelligence to identify novel protein targets and precision biomarkers, ultimately enhancing the translation of research into effective patient treatments.
Turbine
Seed Round in 2021
Turbine Ltd, established in 2015 and headquartered in Budapest, Hungary, specializes in computational biology for cancer drug development. The company's core product is a predictive model that simulates cellular behavior, aiding in the discovery, preclinical testing, and development of cancer therapies. Turbine's platform leverages proprietary Simulated Cell technology and artificial intelligence to identify novel protein targets and precision biomarkers, ultimately enhancing the translation of research into effective patient treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.